Fig. 6: Decision curve analysis unveiled the improved clinical net benefit of the miR-221/222-fitted multivariate models. | Blood Cancer Journal

Fig. 6: Decision curve analysis unveiled the improved clinical net benefit of the miR-221/222-fitted multivariate models.

From: Refining precision prognostics in multiple myeloma: loss of miR-221/222 cluster in CD138+ plasma cells results in short-term progression and worse treatment outcome

Fig. 6

DCA curves of “miR-221/222-fitted” and “control” multivariate prediction models for the overall survival (OS; (A)) and progression-free survival (PFS; (B)) of the patients. Net benefit is plotted against various ranges of threshold probabilities. The control model consisted of R-ISS stage, response to 1st-line chemotherapy, and high-risk cytogenetics.

Back to article page